Gilead Sciences stock: growth
GILDGilead Sciences reported $29.44B in revenue for fiscal 2025, up 2.4% on the prior year, up 3.6% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 3.6% | −1.0% | 12.7% |
| Revenue per share | 3.8% | 0.6% | 15.1% |
| Earnings | 133.3% | −7.3% | no data |
| Earnings per share | 133.8% | −5.8% | no data |
| Free cash flow | 4.7% | −7.4% | 11.9% |
| Free cash flow per share | 4.9% | −5.9% | 14.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $3.03B | −$1.19B | $1.11B |
| 2007 | $4.23B | $1.62B | $1.69B |
| 2008 | $5.34B | $1.98B | $2.03B |
| 2009 | $7.01B | $2.64B | $2.85B |
| 2010 | $7.95B | $2.9B | $2.77B |
| 2011 | $8.39B | $2.8B | $3.51B |
| 2012 | $9.7B | $2.59B | $2.8B |
| 2013 | $11.2B | $3.08B | $2.92B |
| 2014 | $24.89B | $12.1B | $12.26B |
| 2015 | $32.64B | $18.11B | $20.5B |
| 2016 | $30.39B | $13.5B | $16.3B |
| 2017 | $26.11B | $4.63B | $11.31B |
| 2018 | $22.13B | $5.46B | $7.48B |
| 2019 | $22.45B | $5.39B | $8.32B |
| 2020 | $24.69B | $123M | $7.52B |
| 2021 | $27.31B | $6.23B | $10.81B |
| 2022 | $27.28B | $4.59B | $8.34B |
| 2023 | $27.12B | $5.67B | $7.42B |
| 2024 | $28.75B | $480M | $10.31B |
| 2025 | $29.44B | $8.51B | $9.46B |
Revenue by segment
How Gilead Sciences, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Biktarvy$14.3B49%
- Descovy$2.8B9%
- Genvoya$1.5B5%
- Yescarta$1.5B5%
- Trodelvy$1.4B5%
- Sofosbuvir/Velpatasvir$1.3B4%
- Other$6.7B23%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Biktarvy | $14.33B | 48.7% |
| Descovy | $2.76B | 9.4% |
| Genvoya | $1.5B | 5.1% |
| Yescarta | $1.5B | 5.1% |
| Trodelvy | $1.4B | 4.7% |
| Sofosbuvir/Velpatasvir | $1.27B | 4.3% |
| Other | $6.69B | 22.7% |
| Total revenue | $29.44B | 100% |
Revenue by region
Where Gilead Sciences, Inc. generates its revenue.
- United States71%
- Europe17%
- Other12%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $19.35B | $18.19B | $16.27B | $16.65B | $18.22B | $19.27B | $18.88B | $19.44B | $20.59B | $20.88B | 70.9% |
| Europe | $6.37B | $5.31B | $4.01B | $3.81B | $4.14B | $4.87B | $4.47B | $4.31B | $4.63B | $5.06B | 17.2% |
| Other | $4.67B | $2.6B | $1.85B | $1.99B | $2.34B | $3.16B | $3.93B | $3.37B | $3.53B | $3.5B | 11.9% |
| Total revenue | $30.39B | $26.11B | $22.13B | $22.45B | $24.69B | $27.31B | $27.28B | $27.12B | $28.75B | $29.44B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 28 Aug 2026)
- Valuation signal Fairly valued since 11 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.